May 14 2009
Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce that Julianna Lisziewicz, Chief Executive Officer of the Company, will be presenting at the Bio International Convention, to be held from May 18-21, 2009 in Atlanta, Georgia.
Dr. Lisziewicz will discuss DermaPrep, Genetic Immunity's topical Dendritic Cell Targeting delivery system for pathogen-like vaccines. DermaPrep has been clinically tested in combination with the Company's unique vaccine nanoformulation technology that converts antigens (e.g. pDNA, proteins) into pathogen-like nanoparticles to mimic the natural danger signal of the body that results from pathogen exposure. The nanoparticle contains the antigen of the target disease complexed with a polymer to improve its stability and immunogenicity by protecting the antigen from degradation and ensuring the effective antigen presentation of Dendritic Cells. Dendritic Cells in turn generate long-term immunologic memory to protect against relapse. Several animal and human studies (Phase I and II) have demonstrated the safety, tolerability and immunogenicity of this approach.
"I am glad to be a presenter at the Bio International Convention. Our pipeline of products has reached a state of maturity that allows us to begin seeking industry partners for faster commercial introduction. This convention is the perfect venue to share our results and hopefully ink a number of partnership deals," commented Julianna Lisziewicz, CEO of the Company.